SLN
Silence Therapeutics plcCompany Information
- Company Name
- Silence Therapeutics plc
- CIK
- CIK0001479615
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SLN: Nasdaq, SLNCF: OTC
- Fiscal Year End
- N/A
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SLN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 19,429,021
- Shares outstanding
- 47,234,193
- Ownership
- 41.13%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -5.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||
| Cash And Cash Equivalents At Carrying Value | 72 | 6 | 11 | 82 | 42 | 65 | 121 | ||||||
| Short Term Investments | 0 | 64 | 74 | 20 | 72 | 72 | 26 | ||||||
| Other Assets Current | 13 | 11 | 12 | 9 | 14 | 16 | 15 | ||||||
| Accounts Receivable Net Current | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Assets Current | 94 | 103 | 119 | 134 | 149 | 170 | 187 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 10 | 10 | 11 | 11 | 11 | 11 | 9 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 0 | - | - | - | 0 | ||||||
| Other Intangible Assets Net | 0 | 0 | - | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 4 | 4 | 4 | ||||||
| Assets | 106 | 115 | 131 | 147 | 165 | 185 | 203 | ||||||
Liabilities Current | |||||||||||||
| Contract With Customer Liability Current | 0 | 0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Accounts Payable Other Current | -13 | -10 | -13 | -17 | -14 | -19 | -16 | ||||||
| Operating Lease Liability Current | -0 | -0 | -0 | -0 | 0 | -0 | -0 | ||||||
| Liabilities Current | -13 | -10 | -14 | -17 | -15 | -19 | -17 | ||||||
| Contract With Customer Liability Noncurrent | -55 | -55 | -55 | -55 | -56 | -53 | -52 | ||||||
| Operating Lease Liability Noncurrent | -0 | -0 | -0 | -0 | - | - | 0 | ||||||
| Liabilities | -68 | -66 | -69 | -73 | -71 | -73 | -69 | ||||||
Stockholders Equity | |||||||||||||
| Common Stock Value | -10 | -10 | -10 | -10 | -10 | -10 | -10 | ||||||
| Additional Paid In Capital Common Stock | -621 | -620 | -618 | -618 | -615 | -613 | -610 | ||||||
| Retained Earnings Accumulated Deficit | 590 | 578 | 563 | 551 | 530 | 503 | 474 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 3 | 3 | 3 | 3 | 1 | 8 | 12 | ||||||
| Stockholders Equity | -38 | -49 | -62 | -74 | -94 | -113 | -134 | ||||||
| Liabilities And Stockholders Equity | -106 | -115 | -131 | -147 | -165 | -185 | -203 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | ||||||
| Common Stock Shares Issued | 47 | 47 | 47 | 47 | 47 | 47 | 47 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSilence Therapeutics plc (SLN) — SEC Financial Statements & Analysis
Silence Therapeutics plc (SLN) is a pharmaceutical preparations company, incorporated in X0. Silence Therapeutics plc trades on Nasdaq, OTC as: SLN, SLNCF. Silence Therapeutics plc (SLN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Silence Therapeutics plc carries a market cap of $518.66M, a P/E ratio of -8.65x, a P/B ratio of 13.48x, a P/S ratio of 843.35x, an enterprise value of $446.60M, and an EV/EBITDA multiple of -6.57x. On profitability, it posts a gross margin of 79.50%, an operating margin of -11106.83%, a net margin of -9748.46%, a Return on Equity (ROE) of -90.41%, a Return on Assets (ROA) of -44.14%, and a Return on Invested Capital (ROIC) of -171.13%. Per share, it reports EPS of $-1.27, diluted EPS of $-1.27, free cash flow per share of $-0.89, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of -7.42x, a quick ratio of -7.42x, working capital of $107.00M, a debt-to-equity ratio of -1.77x, a debt ratio of -0.64, free cash flow of $-42.27M (TTM), and net debt of $-72.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $518.66M
- P/E TTM
- -8.65x
- EPS TTM
- $-1.27
- P/B TTM
- 13.48x
- ROE TTM
- -90.41%
- ROA TTM
- -44.14%
- Debt To Equity
- -1.77x
- Free Cash Flow TTM
- $-42.27M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Silence Therapeutics plc in?
Silence Therapeutics plc (SLN) operates in the Pharmaceutical Preparations industry.
What exchange does SLN trade on?
Silence Therapeutics plc (SLN) trades on the Nasdaq, OTC.
Where is Silence Therapeutics plc incorporated?
Silence Therapeutics plc is incorporated in United Kingdom.
When was Silence Therapeutics plc (SLN)'s most recent SEC filing?
Silence Therapeutics plc (SLN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is SLN's market cap?
Silence Therapeutics plc (SLN) has a market capitalization of $518.66M as of 2026-06-30.
What is SLN's EPS (earnings per share)?
Silence Therapeutics plc (SLN)'s trailing twelve month EPS is $-1.27 as of 2026-06-30.
What is SLN's ROE (return on equity)?
Silence Therapeutics plc (SLN)'s trailing twelve month Return on Equity (ROE) is -90.41% as of 2026-06-30.
What is SLN's ROA (return on assets)?
Silence Therapeutics plc (SLN)'s trailing twelve month Return on Assets (ROA) is -44.14% as of 2026-06-30.
What is SLN's ROIC (return on invested capital)?
Silence Therapeutics plc (SLN)'s trailing twelve month Return on Invested Capital (ROIC) is -171.13% as of 2026-03-31.
What is SLN's EV/EBITDA?
Silence Therapeutics plc (SLN)'s trailing twelve month EV/EBITDA is -6.57x as of 2026-06-30.